Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10857162 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
US10251896 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
US9872865 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
US11071742 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
US11583542 | AMYLYX | Compositions of bile acids and phenylbutyrate compounds |
Jul, 2040
(16 years from now) |
Relyvrio is owned by Amylyx.
Relyvrio contains Sodium Phenylbutyrate; Taurursodiol.
Relyvrio has a total of 5 drug patents out of which 0 drug patents have expired.
Relyvrio was authorised for market use on 29 September, 2022.
Relyvrio is available in for suspension;oral dosage forms.
Relyvrio can be used as treatment of amyotrophic lateral sclerosis (als) in adults.
Drug patent challenges can be filed against Relyvrio from 29 September, 2026.
The generics of Relyvrio are possible to be released after 27 July, 2040.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 29, 2027 |
Orphan Drug Exclusivity(ODE-411) | Sep 29, 2029 |
Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient
NCE-1 date: 29 September, 2026
Market Authorisation Date: 29 September, 2022
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults
Dosage: FOR SUSPENSION;ORAL